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Abstract 
Background: Many individuals in the community are prescribed psychoactive drugs with sedative effects. 
These drugs may affect their daily functions, of which automobile driving is a major component. 
Objective: To examine the association of three classes of commonly used psychoactive drugs (viz. 
benzodiazepines and newer non-benzodiazepine hypnotics, antidepressants and opioids) with (i) the risk 
of traffic accidents (as indexed by epidemiological indicators of risk); and (ii) driving performance (as 
indexed by experimental measures of driving performance). Methods: A literature search for material 
published in the English language between January 1966 and January 2010 in PubMed and EMBASE 
databases was combined with a search for other relevant material referenced in the retrieved articles. 
Retrieved articles were systematically reviewed, carrying out meta-analyses where possible. Twenty-one 
epidemiological studies (13 case-control and 8 cohort studies) fulfilled the inclusion criteria by estimating 
the accident risk associated with drug exposure (ascertained by blood/urine analysis or prescription 
records). Sixty-nine experimental studies fulfilled the inclusion criteria by testing actual or simulated 
driving performance after administering a single dose or multiple doses. 
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Figure captions: 
Figure 1: Selection process of studies. 
Figure 2: Meta-analysis of case-control studies on benzodiazepines and traffic accidents. df : 
Degrees of freedom. Cochran Q: Test statistic for heterogeneity of studies. I
2
: Percentage of 
variation of study estimate due to heterogeneity (100% * [Q – df] / Q). X
2
: Chi-square 
statistic for significance of the overall effect in DerSimonian-Liard random effects pooling 
method. 
Figure 3: Meta-analysis of cohort studies on benzodiazepines and traffic accidents. Z: Z 
statistic for significance of the overall effect in DerSimonian-Liard random effects pooling 
method. 
Figure 4: Meta-analysis on accident-responsibility studies on benzodiazepines.  










































































Background: Many individuals in the community are prescribed psychoactive drugs with 
sedative effects. These drugs may affect their daily functions, of which automobile driving is 
a major component. 
Objective: The aim of this systematic review was to examine the association of 3 classes of 
commonly used psychoactive drugs (viz. benzodiazepines and newer non-benzodiazepine 
hypnotics, antidepressants and opioids) with 1) the risk of traffic accidents (as indexed by 
epidemiological indicators of risk) and 2) driving performance (as indexed by experimental 
measures of driving performance). 
Methods: A literature search for material published in English between January 1966 and 
January 2010 in PUBMED and EMBASE databases was combined with a search for other 
relevant material referenced in the retrieved articles. Retrieved articles were systematically 
reviewed, carrying out meta-analyses where possible. Twenty one epidemiological studies 
(13 case-control and 8 cohort studies) fulfilled the inclusion criteria by estimating the 
accident risk associated with drug exposure (ascertained by blood/urine analysis or 
prescription records). Sixty nine experimental studies fulfilled the inclusion criteria by testing 
actual or simulated driving performance after administering a single dose or multiple doses. 
Results: Two meta-analyses showed that benzodiazepines are associated with a 60% (for 
case-control studies: pooled odds ratio [OR]: 1.59, 95%CI: 1.10–2.31) to 80 % (for cohort 
studies: Pooled incidence rate ratio: 1.81, 95%CI: 1.35–2.43) increase in the risk of traffic 
accidents and a 40% (pooled OR: 1.41, 95%CI: 1.03–1.94) increase in ‘accident-
responsibility’. Co-ingestion of benzodiazepines and alcohol was associated with 7.7-fold 
increase in the accident risk (Pooled OR: 7.69, 95%CI: 4.33–13.65). Subgroup analysis of 
case-control studies showed a lower benzodiazepine-associated accident risk in elderly (>65 



































































95% CI: 1.31–3.73), a result consistent with age-stratified risk differences reported in cohort 
studies. Anxiolytics, taken in single or multiple doses during daytime, impaired driving 
performance independent of their half-lives. As for hypnotics, converging evidence from 
experimental and epidemiological studies indicates that diazepam, flurazepam, 
flunitrazepam, nitrazepam and short-half-life non-benzodiazepine hypnotic zopiclone 
significantly impair driving at least during the first 2-4 weeks of treatment. The accident risk 
was higher in the elderly (> 60 years) who use tricyclic antidepressants (TCAs), however the 
evidence for an association of antidepressants with accident risk in  younger drivers was 
equivocal. Sedative but not non-sedative antidepressants were found to cause acute 
impairment of several measures of driving performance. Limited epidemiological research 
reported that opioids may be associated with increased accident risk in the first few weeks of 
treatment.  
Conclusions: Benzodiazepine use was associated with a significant increase in the risk of 
traffic accidents and responsibility of drivers for accidents. The association was more 
pronounced in the young drivers. The accident risk was markedly increased by co-ingestion 
of alcohol. Driving impairment was generally related to plasma half-lives of hypnotics, but 
with notable exceptions. Anxiolytics, with daytime dosing, impaired driving independent of 
their half-lives. TCAs appeared to be associated with increased accident risk at least in the 
elderly, and caused acute impairment in driving performance. Opioid users seemed to be at a 
higher risk of traffic accidents; however experimental evidence is scarce on their effects on 








































































Many individuals in the community are prescribed psychoactive drugs with sedative 
effects such as benzodiazepines, tricyclic antidepressants (TCAs) and opioids. The vast 
majority of those who are treated with these drugs are outpatients and expected to carry out 
their daily activities in a similar manner to healthy individuals. However, these drugs can 
adversely affect the cognitive and psychomotor functions underlying daily activities, and 
some of those functions (e.g. reaction time, attention, visuospatial skills) are considered 
important in automobile driving.
[see 1, 2 for reviews, 3]
 
The effects of drugs on driving safety have been previously examined using 
epidemiological and experimental study designs. The epidemiological studies examine this 
relationship in terms of traffic safety by measuring the association between use of sedative 
psychotropic drugs and the risk of traffic accidents, while experimental studies approach the 
question by examining whether administration of drugs is likely to impair driving 
performance. The focus of the present review is to explore the role of three classes of 
psychoactive drugs (viz. benzodiazepines and newer non-benzodiazepine hypnotics, 
antidepressants and opioids) in traffic safety by combining the evidence from 
epidemiological and experimental studies, because each type of study in isolation, fails to 
establish drugs as a causative factor in traffic accidents. 
The outcome of interest in epidemiological studies is traffic accidents (in most 
instances injurious or fatal accidents) which are a major outcome of immediate practical 
significance. Being observational studies, they fall short of establishing a cause and effect 
relationship between drug use and traffic accidents, i.e., detection of a drug in a driver who 
met with an accident does not necessarily mean that the drug was a cause for the accident.
[4]
 
Accident responsibility studies attempt to overcome this limitation by establishing that the 



































































not responsible for accidents. Therefore the present review also focuses on accident 
responsibility studies. 
The aim of experimental studies is to determine the causative role of single or a few 




[e.g. 8, 9, 10]
 Experimental studies can eliminate many of the limitations 
of epidemiological studies, but mostly at the cost of compromising the ecological validity. 
Driving performance is almost always tested in a highly controlled environment where only 
certain components of driving behaviour are examined through specific driving tasks. Certain 
driving tests however have achieved a greater ecological validity within a controlled 
environment and had been also validated against surrogate markers of traffic safety. For 
example, in a standardised driving test developed by O’Hanlon and colleagues in early 
1980s, the primary outcome measure is the driver’s ability to maintain the lateral position of 
the vehicle in the driving lane. Cognitive models of driving define such processes as 
‘operational’ processes of driving which are necessary for stable driving.
[11-13]
 The degree of 
weaving of the vehicle (termed standard deviation of lateral position: SDLP) was calibrated 
against different blood levels of alcohol which is a known risk factor for traffic accidents.
[5]
 
Several recent reviews have comprehensively analysed the effects of different doses of 
commonly used benzodiazepine and non-benzodiazepine hypnotics
[14, 15]
  and antidepressants 
[16]
 on this measure of lateral position control in highway-driving. While impaired 
performance in the above driving test suggests the participant is unfit for highway driving, 
unimpaired driving performance does not necessarily mean that one is able to drive safely, 
particularly in complex driving environments where the driver has to interact with other 
vehicles, pedestrians, traffic signs and other roadside objects. According to cognitive models 
of driving, more complex processes necessary to interact with the external environment and 





































































 Different actual and simulated driving tests have attempted to tap these 
higher level aspects of driving and are reviewed in the present paper. 
Many recent epidemiological studies
[e.g.17, 18, 19]
 and reviews of experimental 
studies
[14-16]
 emphasize the differences in the effects of individual drugs (even if they are in 
the same class of drugs). Accordingly, the present review also will focus down onto the level 
of individual drugs. In addition, we also focus on different subject factors (patients vs. 




The broad objective of the present study was to systematically review the literature to 
find out whether three classes of commonly used psychoactive drugs (benzodiazepines and 
newer non-benzodiazepine hypnotics, antidepressants and opioids) are associated with 
increased risk of traffic accidents and impaired driving. More specifically we aimed to 
examine; 
1) whether use of each of these drugs are associated with increased risk of traffic 
accidents (as indexed by risk estimates measured in analytical epidemiological 
studies) and 
 2) whether experimental administration of these drugs causes impairment in driving 
performance (as indexed by quantitative measures of driving performance in a real 
vehicle or a driving simulator). 
 
2. METHODOLOGY 



































































We conducted a literature search on the PUBMED and EMBASE databases for 
material published between January 1966 and 31 January 2010. The search was limited to 
human studies published in English. Two sets of search terms were used. The first set 
consisted of the EMTREE / MeSH terms ‘benzodiazepine derivative’, 'zaleplon', 'zopiclone', 
'zolpidem', 'zolpidem tartrate', 'eszopiclone', 'antidepressant agent’ and ‘opiate agonist’. The 
second set  included the EMTREE / MeSH terms ‘traffic accidents’, ‘traffic safety’ and ‘car 
driving’ and general search term ‘driving’. By selecting the ‘explosion’ option, the search 
also incorporated the terms that are subtopics (e.g. individual drugs in a particular class of 
drugs) of each of the above EMTREE / MeSH terms. The articles that contained at least one 
term from each of the above sets of search terms were extracted for consideration for 
inclusion in the review. The reference lists of the eligible articles were searched for any other 
relevant literature. 
 
2.2. Inclusion criteria 
Inclusion criteria for epidemiological studies were; a) cohort or case-control study 
design or variants such as case-crossover studies (survey designs and other descriptive 
studies were excluded) and b) explicitly stated exposure ascertainment (e.g. detection of 
drugs in body fluids, records of drug prescription) and outcome ascertainment (i.e. traffic 
accidents or subcategories such as ‘traffic accidents required hospitalisation’ or ‘fatal traffic 
accidents’). The research methods of epidemiological studies were assessed based on the 
appropriate fields outlined in STROBE (Strengthening the Reporting of Observational 
Studies in Epidemiology) statements for case-control studies and cohort studies.  
The inclusion criteria for experimental studies were; a) administration of a single dose or 
multiple doses of a relevant drug to at least one of the study groups and b) implementation of 



































































psychomotor functions related to driving by laboratory tests were excluded). The 
methodology of the experimental studies was evaluated under 4 categories: experimental 
design, selection of study samples, pharmacological manipulation and outcome measures. 
 
The initial search retrieved 1271 articles. Exclusion of the papers which did not meet 
the inclusion criteria are summarised in Figure 1. This initial literature search retrieved 15 
epidemiological studies and 54 articles on experimental studies. A review of the reference 
lists produced an additional 6 epidemiological studies and 9 experimental studies. Thus in 
total, 21 epidemiological studies and 69 experimental studies (in 62 papers) met the 
aforementioned inclusion criteria. Of the 21 epidemiological studies 13 were case-control 
studies (Table 1) and 8 were cohort studies (Table 2). Nineteen epidemiological studies 
investigated exposure to benzodiazepines, 6 to antidepressants and 7 to opioids. Of the 69 
experimental studies, benzodiazepines and/or ‘z drugs’ were tested in 48 studies 
(Supplementary Table 1), antidepressants in 20 (Supplementary Table 2) and opioids in 3 
(Supplementary Table 3). 
 
2.3. Meta-analysis 
The retrieved epidemiological studies were pooled for meta-analyses in the instances 
where adequate numbers of studies with required data were available. A random-effects 
model analysis (DerSimonian-Laird method) was employed to calculate the pooled estimates 
as it does not assume that each component study of the meta-analysis is derived from the 
same population, and hence allowed pooling statistically heterogeneous studies without 
compromising the statistical validity of the results. However, random effects modelling 
generated wider confidence-intervals for the pooled estimate than fixed-effects modelling 



































































planned in the instances where there was a severe statistical heterogeneity. However, this 
could be carried out only for the case-control studies on benzodiazepines (based on age), 




3.1. EPIDEMIOLOGICAL STUDIES: RISK OF TRAFFIC ACCIDENTS AND USE OF 
BENZODIAZEPINES, ANTIDEPRESSANTS AND OPIOIDS 
 
The methodology and results of 13 case-control studies and 8 cohort-studies are 
summarised with the limitations specific to individual studies noted in Tables 1 and 2, 
respectively. 
Two distinct sampling methods can be observed in epidemiological studies. Seven 





after traffic accidents whereas controls were recruited either from the victims of traffic 
accidents or randomly from the roadside.
[20, 22]
 Drug exposure was ascertained by analysing 
the blood or urine samples. The main advantage of this method is availability of confirmatory 
evidence for occurrence of the drug under question at the time of accident.  
In other case-control studies (except one, where exposure was ascertained through an 
interview
[26]
) and all cohort studies, both exposure and outcome ascertainment was registry-
based. Accident involvement was ascertained from entries in hospital admission or general 
practice databases or road accident registries, and drug exposure was ascertained by means of 
prescription entries in drug prescription databases. Outcome ascertainment was based on 
motor registry data or medical records. The number of days for which the drugs are 



































































showed whether the patient was prescribed (and hence likely to be taking) the drugs at the 
time of accident. The advantage of this approach is the ability to enlist large numbers of 
subjects thus increasing the power of the study.  
However this registry-based approach has also introduced certain biases common to 
many of these observational studies. Firstly, it introduces an exposure ascertainment bias. It 
is impossible to know whether patients had been actually taking the prescribed drugs during 
the designated ‘exposed period’ and had not been taking any left-over prescribed drugs or 
drugs obtained off-prescription during the ‘unexposed period’. Nevertheless, such false 
exposure ascertainment shifts the results towards null findings and hence does not threaten 
the validity of any detected positive association between drug use and traffic accidents. 
Secondly, only a certain percentage of the outcomes (i.e. traffic accidents) are recorded in the 
databases. Particularly less serious accidents, which is likely to represent a significant 
proportion of all accidents, might have not been entered. For example, studies that recruited 
accident victims from hospitals 
[4, 20-23]
 only includes injurious traffic accidents where the 
injuries were serious enough to seek medical assistance. Thirdly, data on some important 
confounders may have not recorded in the registries. Many studies did adjust the analyses or 
matched the samples for demographic variables (e.g. age, gender) but missed some other 
important confounders such as underlying illnesses for which the drugs are prescribed (e.g. 
depression), which can also affect driving. Inevitably, this may have had left a certain degree 
of residual confounding. Other limitations and potential biases specific to individual 
epidemiological studies are noted in Tables 1 and 2. 
3.1.1. Benzodiazepines and ‘z drugs’ 
Of the three classes of drugs, benzodiazepines were the most extensively studied. 
Benzodiazepines have been studied in 12 case-control studies and 6 cohort studies. Of these, 
1 case control study
[27]
 and 2 cohort studies
[18, 28]



































































of ‘z’ drugs. Based on these studies we conducted three separate meta-analyses for case-
control studies, cohort studies and accident responsibility studies. 
1) Case-control studies on benzodiazepine exposure and traffic accident risk (Figure 
2): Of the 12 case control studies, 8 examined whether exposure to benzodiazepines is 
associated with increased odds of traffic accidents. Two studies
[22, 27]
 did not report the 
exposure data and numbers of traffic accidents in exposed and unexposed periods so that 
those two studies could not be included in the meta-analysis. However both these studies 
showed a significant association between benzodiazepine exposure and traffic accidents. The 
first was a case cross-over study where, in a group of drivers involved in traffic accidents, the 
proportion exposed to benzodiazepines on the day of accident (i.e. the case period) was 
compared with the proportion exposed on a within-subject control period (i.e. same day of 
the week in up to 18 weeks prior to accident date).
[27]
 The adjusted OR for all 
benzodiazepines in this study was 1.62 (95% CI 1.24 - 2.12) suggesting higher accident risk 
associated with benzodiazepines use. The second study reported benzodiazepine exposure 




The other six publications contained adequate data for analysis and were included in 
the meta-analysis (see Figure 2). The studies showed a marked statistical heterogeneity 
(Cochran Q = 16.20, p = 0.006. I
2
 = 69.1%). Nonetheless, the overall association between 
benzodiazepine exposure and traffic accident risk was significant (p=0.014), showing that 
benzodiazepines are associated with a 59% increase in traffic accident risk (pooled OR 
=1.59, 95% CI: 1.10 – 2.31). A previous meta-analysis by Rapoport et al. 2009 used the same 
set of studies. However, the authors included subject counts only for long-acting 
benzodiazepines in the Hemmelgarn et al. 1997 study in their analysis.
[29]
 We included the 



































































life distinction has not been made in the other studies included in the current meta-analysis. 
Indeed some other studies in the meta-analysis also included subjects predominantly exposed 
to short acting benzodiazepines (e.g. the majority of the subjects of the Leveille et al. 1994 
study were exposed to triazolam).  
2) Cohort studies on benzodiazepine exposure and traffic accident risk (Figure 3): Of 
the 6 cohort studies, two
[18, 19]
 included the same data-sources used in a previous study
[30]
 and 
thus those two articles were excluded. One other article was also excluded as it did not have 
enough information to calculate risk.
[28]
 However, this study showed a significantly high 
incidence rate ratio (IRR) suggesting benzodiazepines are associated with increased traffic 
accident risk. The remaining three studies
[30-32]
 were included in the meta-analysis (see 
Figure 3). Similar to case-control studies, there was a significant heterogeneity among 
individual study results (Cochran Q = 6.65, p = 0.036. I
2
 = 70%). Nonetheless, the overall 
effect of exposure on traffic accident risk was highly significant (p<0.0001), with an 81% 
increase of accident rates in benzodiazepines users (pooled IRR: 1.81, 95% confidence 
intervals: 1.35 – 2.43). 
3) Case-control studies on benzodiazepine exposure and traffic accident 
responsibility (Figure 4): Six case-control studies determined whether benzodiazepines are 
more commonly detected in the blood of drivers responsible for accidents than in the victims 
(i.e. drivers who were involved but not responsible for the accident or passengers). One of 
the studies was excluded due to inadequate data
[27]
; however this study showed a significant 
association between accident responsibility and benzodiazepine exposure. The other 5 studies 
were included in the meta-analysis. In the selected studies, driver responsibility was 
ascertained using evidence of ‘unsafe driving actions’ at the time of accident
[25]
, information 
from police / researcher investigation findings
[21]
 and comprehensive scoring systems based 
on drivers’ attempts to mitigate an accident
[4, 33]
 as well as subjective recall.
[26]



































































was the smallest and had the widest confidence intervals.
[26]
 There was a marginally 
significant heterogeneity among the studies (Cochran Q = 9.30, p=0.054. I
2
 = 57%). The 
overall effect (p=0.034) showed benzodiazepines were significantly associated with a 41% 
increase in accident responsibility (Pooled OR: 1.41, 95% CI: 1.03 – 1.94).  
These 3 meta-analyses clearly confirm benzodiazepines, as a group, are associated 
with increased accident risk for drivers. However, different subgroup analyses in individual 
studies suggest several other drug and driver factors can modify this association. These 
confounding factors include age of drivers, therapeutic use (i.e. day-time use as anxiolytics 
and night time use as hypnotics), half-life of the drug, drug dose, duration of benzodiazepine 
use and co-ingestion of other psychoactive substances. We conducted subgroup meta-
analyses based on age and co-ingestion of alcohol but not for each of the above factors 
because the numbers of studies were limited. 
Age:  
Two independent sets of evidence suggest benzodiazepine associated traffic accident 
risk is lower in the elderly. Firstly, we estimated the pooled ORs of the 3 case-control studies 
that only involved old (>65 years) drivers
[26, 34, 35]
 and 3 case control studies that comprised 
drivers over a wider age range starting from 18 years.
[20, 23, 36]
 There was no significant 
statistical heterogeneity among the studies once the studies were sub-grouped according to 
age (Older group: Cochran Q = 2.15, p = 0.34. I
2
 = 6.9%. Younger group: Cochran Q = 3.19, 
p = 0.20, I
2
 = 37.3%). The pooled OR of the older subgroup (OR: 1.13, 95% CI: 0.97 – 1.31) 
was less than that of the younger subgroup (pooled OR: 2.21, 95% CI: 1.31 – 3.73). 
Secondly, of the epidemiological studies that had participants across a wider age range, four 
have reported the age stratified risk estimates for traffic accidents.
[19, 27, 30, 37]
 Of these, three 
report lower risk in older groups than in younger groups
[19, 27, 30]
 while one reported similar 
ORs in the young (<60 years) and the old (>60 years).
[32]



































































also report age-stratified risks, and found higher responsibility in young benzodiazepine users 
but not in their older counterparts.
[25]
 
Therapeutic use and dosing regimen:  
Anxiolytics are taken usually in single or multiple doses in daytime and thus it is 
possible that they increase accident risk irrespective of their short half-lives. Two cohort 
studies and one case-control study have categorised benzodiazepines as anxiolytics or 
hypnotics. All 3 showed increased risk with anxiolytics.
[27, 30, 32]
 Two cohort studies showed 
an increased risk in the groups using hypnotics
[30, 32]
 while the case control study showed that 
as a group, hypnotics did not significantly increase traffic accident risk.
[27]
 Hypnotics are 
taken at bedtime and the following-day adverse effects may depend on the duration of action 
of the individual drugs. 
Half-life of drugs:   
Two studies have examined the effect of elimination half-life of benzodiazepines, one 
on the risk of traffic accidents on older (>65 years) adults
[34]
 and the other on accident 
responsibility.
[25]
 The first study categorised benzodiazepines into short (≤ 24 hours) and 
long elimination half-life (> 24 hours) drugs.
[34]
 Long-half-life drugs but not short-half-life 
drugs were associated with increased accident risk in the elderly. The second categorised 
benzodiazepines into short (< 6 hours, mainly midazolam), intermediate (6-12 hours) and 
long elimination half-life (>24 hours) drugs.
[25]
 New users of long-half-life and intermediate-
half-life benzodiazepines were at a significantly higher risk of accident responsibility whilst 
those exposed to short-half-life benzodiazepines showed no increased risk compared to 
controls. 
Where individual drugs have been analysed, the accident risk is increased with the 
use of diazepam
[19, 28, 32]
 even after 2-4 weeks into treatment, but not with oxazepam.
[32]
 



































































those who were not responsible.
[25]
 Although therapeutic use of each drug was not specified 
in the studies, these drugs are more often prescribed as anxiolytics.  
Five studies report accident risks associated with several different benzodiazepine and 






 appear to increase the risk of traffic accidents. However, medium-




 and short-acting 
benzodiazepines triazolam
[32]
 were also found to increase the accident risk. No significant 
effect was observed with very-short acting hypnotic midazolam.
[25]
 The short acting non-
benzodiazepine hypnotic zopiclone was examined in 3 studies. One case-control study shows 
a 4-fold increase in accident risk
[27]
 while a large scale cohort study reports a 2-fold increase 
in accident risk.
[18]
 The other study did not show a significant change in the accident risk 
with zopiclone.
[28]
 For the short-acting hypnotic zolpidem, the large-scale study reports a 
two-fold increase in risk
[18]
 while the other report no significant effect.
[28]
  
Duration of use:  
Five cohort studies have examined the traffic accident risk of benzodiazepines during 
the first 1-4 weeks after prescription and all found increased risk of traffic accidents.
[18, 28, 30, 
32, 38]




Drug dose:  
Three epidemiological studies examined the dose-response relationship between 
benzodiazepines and traffic accidents.  They showed that higher benzodiazepine doses are 
associated with greater accident risk
[27, 31]
 and higher benzodiazepine concentrations in blood 
are associated with accident responsibility of drivers.
[4]
 The last study reported higher 
accident responsibility associated with therapeutic and supratherapeutic benzodiazepine 





































































Antidepressants were examined in 3 case-control studies and 3 cohort studies. One 
study, where all antidepressants were considered as a single group did not show a significant 
increase in traffic accident risk,
[32]
 or accident responsibility.
[26]
 There were too few studies 
in each category with necessary data to perform a meta-analysis. 
There is no clear distinction between sedative and non-sedative antidepressants in 
their association with traffic accidents in patient groups investigated in epidemiological 
studies. In younger populations, two studies show no significant increase in accident risk 
either with tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors 
(SSRIs)
[27, 28]
 while one reports an increased risk with both sedative and non-sedative 
antidepressants.
[38]
 However, in the elderly, the sedating antidepressants do appear to 
increase the traffic accident risk. Two epidemiological studies have studied antidepressants 
and accident risk in older drivers (> 60 years). Both show that TCA use increased the risk,
[31, 
35]
 with one study demonstrating that the risk increases with dose.
[31]
 However, these studies 
have not examined the effects of non-sedating antidepressants and thus there is insufficient 
data to make any evaluation of newer antidepressants.  
 
3.1.3. Opioids 
Risk of traffic accidents associated with prescription use of opioids has been 
examined in 4 cohort studies and one case control study. Of the 4 cohort studies, 2 had 
overlap of data sources
[17, 30]
 and one did not have adequate information to calculate risk.
[28]
 
Therefore a meta-analysis was not performed on epidemiological studies of opioids. 
Therapeutic use of opioids (as a group) was associated with a higher risk of traffic 
accidents in young drivers.
[28, 30]












































































 may be associated with increased accident risk at least during the first 4 weeks of 
use.  In contrast to prescription-based studies, the detection of opioids in blood in drivers was 
associated neither with the accident risk
[22]




3.1.4. Drug-alcohol interactions and drug interactions 
Drug-alcohol interactions are reported in 3 case-control studies. Benzodiazepine-
alcohol combinations always showed a greater risk of traffic accidents
[22]
 and accident 
culpability.
[4, 21]
 All three studies consisted of adult drivers over a wide age range and 
determined benzodiazepine and alcohol exposure with blood / urine sample analysis. In each 
study, the reported OR for benzodiazepine-alcohol combination was higher than that 
observed with either benzodiazepines or alcohol alone (Table 1). The three case control 
studies were combined in a random-effects model meta-analysis (Figure 5). The results show 
that benzodiazepines can increase the odds of traffic accidents by 7.7 times (Pooled OR: 
7.69, 95% CI: 4.33 – 13.65), suggesting a marked synergistic effect of alcohol-
benzodiazepine combination on risk of traffic accidents. These studies do not specify the 
blood alcohol levels but all 3 have included some participants with blood alcohol levels 
below the legal limits for driving. 
One case-control study and one cohort study report combined effects of psychoactive 
drugs on traffic accidents, both in elderly drivers. In the case-control study, use of one drug 
was associated with 30% increase in the accident risk, which further increased to 100% with 
the use of two or more drugs.
[35]
 Similarly, the cohort study showed 110% increase in traffic 






































































3.2. EXPERIMENTAL STUDIES: EFFECTS OF BENZODIAZEPINES, 
ANTIDEPRESSANTS AND OPIOIDS ON DRIVING PERFORMANCE 
 
3.2.1. Appraisal of the methodology: 
Any methodological concerns specific to each study are noted against the respective 
studies in Supplementary Tables 1-3. Table 3 summarises the different methodological 
approaches of the 69 experimental studies.  
 
3.2.1.1. Experimental design 
Of the 69 studies, 63 were double-blind placebo-controlled studies whereas 6 were of 
other designs. Of the 63 double-blind placebo-controlled studies, 57 were within-subject 
crossover studies (where the same group of subjects were tested under different treatment 
conditions) thus ensuring maximum control over individual variations of driving 
performance. In many studies, attempts had been made to minimise systematic changes in 
performance across treatment conditions by providing adequate practice to participants and 
by randomising treatment order. The participants were assigned into separate treatment or 
placebo groups in the other 6 double-blind placebo-controlled studies (3 randomized, 3 not 
specified).  
Of the 6 experimental studies with other designs, the participants were patients in 4 
studies.
[39-42]
 Single groups of patients were tested before and after treatment in two of these 
studies, whereas a control group treated with an active drug were included in the other two.  
The remaining two studies where healthy volunteers were tested, one was a randomised 
double-blind study in which lorazepam served as an ‘active-control’ drug
[7]
 whilst the other 






































































3.2.1.2. Study samples 
 The participants in the majority of the studies were healthy volunteers. Although 
healthy-volunteer studies examine the effect of a particular dose of a specific drug on driving 
performance, they cannot examine the interactive effects of the drugs and the conditions for 
which these sedative drugs are commonly prescribed (e.g. depression, insomnia, anxiety 
disorder, chronic pain) on driving. However, this ‘confounding by indication’ is accounted 







 and chronic pain.
[41, 53]
 
 Participants of almost all experimental studies were relatively young. Of the 
69 studies, only four
[54-57]
 had elderly participants. 
  
3.2.1.3. Pharmacological manipulation 
 Driving performance was tested after one or few doses of drugs to examine the acute 
effects and / or after several days of administration to find out subacute / subchronic effects. 
All drugs were orally administered (except one study where fentanyl was administered 
transdermally) in therapeutic doses. Adequate wash-out periods were ensured between 
treatment conditions in all crossover studies. 
The driving impairment observed in drug naïve individuals with fixed, single / short-
term dosing regimes of experimental studies does not portray the full spectrum of impairment 
that can occur in real-life situations. For instance, the effects of supratherapeutic doses (that 
might occur with deliberate self-poisoning) on driving may be much greater, whereas 
patients on long-term medication (especially benzodiazepines and opioids) show varying 
degrees of tolerance so that may not exhibit the same degree of impairment observed in drug 




































































3.2.1.4. Driving task and outcome measures 
 Forty nine studies have carried out actual driving tests while 21 have used driving 
manoeuvres performed in a driving simulator.  
Actual car-driving tests have a better ecological validity, but safety concerns in 
pharmacological experiments preclude testing actual driving in traffic. A standardised 
highway driving test developed by a research group in The Netherlands had been used in 31 
experimental studies retrieved in the current review.
[5 for technical details]
 The primary aim of the 
driving task is to maintain a constant lateral position and constant speed of 95km/h. The main 
outcome measure, ‘standard deviation of lateral position (SDLP)’ indicates the degree of 
weaving of vehicle from the intended path and in turn depends on steering control. A 
secondary outcome, ‘standard deviation of speed (SDS)’ is a measure of variability of speed 
and depends on accelerator control. The driver sometimes has to interact with normal traffic 
(e.g. overtaking a slow vehicle); however, these segments are not included in calculating 
SDLP and SDS. Thus, the outcome measures do not directly reflect driving ability in normal 
traffic. Rather, the test examines the driver’s ability to operate the basic controls of the 
vehicle for stable highway driving at a constant speed.  
Eight other actual driving experiments focus on more complex driving manoeuvres 
albeit on a closed-course. These tasks include manoeuvring around bollards (slalom task), 
gap estimation, reversal and parking.
[6, 50, 58-61]
 Brake reaction time was an outcome measure 
in 7 studies on actual driving.
[58, 62-66]
 One limitation of these studies is that being closed-
course tests, subjects may not have had the same safety concerns as in open-road driving. 
Driving simulator tests offer a safe alternative to on-the-road driving. Some simulator 
studies have measured mean variance of lateral position and mean variance of speed which 
are comparable with SDLP and SDS, respectively. However there are two main limitations in 



































































quality of the driver-vehicle-environment interaction compromises the ecological validity of 
the tests. Although participants used at least some driving controls found in a real vehicle 
(i.e. steering, brake) in the tests, there is a wide variation of the nature of the driving scenes 
and the perceptual feedback generated by the vehicle. For instance, in the simplest simulators 
tests, subjects had to perform a continuous tracking task (with steering) and a secondary 
reaction time task (using a foot pedal) in response to relatively abstract visual stimuli,
[10, 67-69]
 
whereas the most complex simulator tests employed more life-like driving scenarios and 
emulated the forces acting upon an actual moving vehicle.
[43]
 Secondly, subjects performing 
simulated driving tests may not consider the safety factor as much as those who undergo real 
driving tests, so that the driving errors in simulated driving tests may exaggerate the actual 
risk of driving errors in real-life driving. 
Pooled estimates of SDLP for different doses of short and long-acting 
benzodiazepines have been calculated in a recent meta-analysis.
[29]
 The authors report nightly 
doses equivalent to ≤ 5mg of diazepam significantly increase SDLP the following morning 
but not in the following afternoon. Doses equivalent to 10mg or more of diazepam caused a 
larger increase in SDLP. However, the strength of the experimental studies is the ability to 
assess the different doses of specific drugs on driving performance at different time intervals 
after dosing, whereas calculating pooled estimates across clinically heterogeneous studies 
may lead to loss of valuable information. In this respect, the patterns of impairment of SDLP 





 have been reviewed recently by the original research group, comparing the 
impairment observed with drugs with what is observed with different blood alcohol levels 
(0.05, 0.08 and 0.1g/dl). However, these reviews do not comprehensively review the effects 



































































driving studies. Thus the present review on experimental studies evaluates the effects of 
individual drugs on both actual and simulated driving tests.  
 
3.2.2. Benzodiazepines and ‘z’ drugs 
All 49 studies that we retrieved administered benzodiazepines orally in therapeutic 
doses. The doses were generally equivalent to 10-20mg of diazepam in almost all studies. 





 and lorazepam 0.5mg in one.
[52]
 Two different dosing regimens which 
correspond to their therapeutic use have been applied by researchers in testing anxiolytics 
and hypnotics. The common design for anxiolytics was to test driving performance half-an-
hour to about 5 hours after dosing. Hypnotics were always administered at night (replicating 
their therapeutic use) and driving was tested in the following morning (9-10 hours after 
dosing) or afternoon (16-17 hours after dosing). 
 
3.2.2.1. Benzodiazepine anxiolytics 
The results obtained in our search include 5 anxiolytics viz. diazepam, lorazepam, 
alprazolam, clobazam and medazepam. The latter two drugs are not widely used at present. 
Diazepam:  Diazepam was tested in 11 studies. Driving performance was assessed at 
different times post-dose, ranging from 30 minutes
[9]
 to 5 hours.
[67]
 Acute increase in 
SDLP
[72]
 and brake  reaction time
[62]
 has been observed after a 10mg dose in on-the-road 
driving tests. A single 5mg dose did not cause a significant increase in SDLP in healthy 
volunteers,
[72]
 but did increase with thrice daily dosing.
[52]
 The impairing effect of the latter 
dosing regimen was observed up to 7 days in healthy volunteers
[52]
 and up to 3 weeks in 
patients with anxiety.
[51]
 These observations suggest that even administered in low doses, 



































































impairment. In driving simulator tests, 10-15 mg doses caused increased collisions,
[9]
 
increased tracking errors and reaction times
[67, 69]
 and impairments in composite measures of 
overall driving performance.
[54, 73]
  In the last study, driving impairment persisted even after 1 
week of treatment. One driving simulator study did not show a significant effect after 
diazepam 0.11mg/kg body weight (~7mg) or 0.22mg/kg body weight (~15mg).
[43]
 This is the 
only non-blind study (healthy volunteers knew what drug they had taken) included in this 
review. The authors argue that those who take sedative drugs in real-life know that the drugs 
may affect their driving performance and thus might take extra effort to compensate. 
However, there was a wide inter-subject variability in driving performance in this study 
probably attributable to the complex driving task and relatively short practice session and 
these factors may also account for the lack of significant effects of diazepam. In summary, 
the experimental studies indicate that diazepam can impair a wide range of task processes in 
driving, and the impairment appears to be significant even after 3 week of continuing 
treatment. These findings are consistent with the epidemiological evidence that showed 
increased accident risk in diazepam users.
[19, 28, 32]
 
Lorazepam: Lorazepam was tested in 5 studies. SDLP was the outcome measure in 3 
experiments and all showed a significant increase with lorazepam even after 1 week of 
treatment.
[52, 74]
 Of these, one study was on a group of patients with anxiety and the 
experimenters continued treatment for 2 weeks and found a significant impairment even at 
the end of this period.
[52]
 Two closed-course studies show that the drug can cause increased 
brake reaction time and impairment of more complex driving manoeuvres including parking, 
turning and avoiding obstacles.
[7, 58]
   
Alprazolam: The 2 studies on alprazolam showed a 1mg dose can severely impair 
highway driving performance as indexed by SDLP.
[75, 76]
 Sustained-release preparation of the 





































































Clobazam: No significant acute impairment was detected in different driving 
manoeuvres after 3 days of treatment with 10mg t.i.d.
[62]
 or after 20mg morning.
[58]
 One other 
study detected impairment after 6 days of treatment.
[6]
 
Medazepam: The long-acting anxiolytic medazepam caused driving impairment in patients 




3.2.2.2. Benzodiazepine and newer hypnotics 
   The effect of nocturnal doses of hypnotics on driving in the following morning 
generally depends on the half-life; however, there are some exceptions. The long-half-life (> 
24 hours) hypnotics include flurazepam, flunitrazepam and nitrazepam. 
Flurazepam (half-life of active metabolite: 40-250 hours): Flurazepam was tested in 6 
driving performance studies and all report impairment with the drug. One to 2 days of 
treatment caused a significant increase in SDLP and SDS that lasts up to 10-11 hours after 
dosing in healthy volunteers with 30mg, and up to 16-17 hours in patients with insomnia 
after 15-30mg.
[5, 46]
 One study on patients showed the following morning’s impairment was 
persistent even after 1 week of continuing treatment.
[46]
 Another actual driving experiment 
found impaired manoeuvring skills in a slalom task 12 hours after a 15mg dose.
[61]
 Driving 
simulator tests showed increased tracking error and brake reaction time and reduced speed of 
driving.
[10, 77]
 These findings are consistent with the Neutal et al. 1995 study where 
flurazepam was associated with a 5-fold increase in the risk of injurious traffic accidents.
[32]
 
Flunitrazepam (half-life: 18-26 hours. Active metabolite: 36-200 hours) : A single 
2mg dose of flunitrazepam did not affect the SDLP after 10 hours in a group of young 
patients with sleep disturbances in one study,
[47]
 but did cause a significant increase which 
lasted 16-17 hours after 2 doses in another.
[5]
 This may be due to accumulation of this long-



































































showed impaired steering control which lasted after 7 days of treatment in a group of patients 
with insomnia.
[45]
 Of the three driving simulator studies, one also reports increased lateral 
deviation and speed variation 10 hours after 1mg dose.
[78]
 These experimental findings 




Nitrazepam (half-life: 15-38 hours): Nitrazepam was tested in 2 studies. A10mg dose 
increased SDLP which was observed 16-17 hours after a nocturnal dose in a group of young 
women with insomnia.
[44]
 This impairment persisted even after 8 days of continuing 
treatment. This evidence supports the epidemiological findings where nitrazepam was 
associated with 170% increase in traffic accidents in the first week of use.
[18]
 A lower dose 
(5mg) caused increased brake reaction time in a driving simulator 9 hours after intake, but 




Three other hypnotics (temazepam, loprazolam, lormetazepam) extracted in this 
review have intermediate plasma half-lives (8-24 hours).  
Temazepam (8-22 hours):  All 5 studies that tested the effects of temazepam used 
20mg nightly doses. SDLP was not significantly affected either in healthy elderly volunteers 
after a single dose
[79]
 or in young women with insomnia who received 3 consecutive doses
[44]
 
the following morning (i.e. 10 hours after dosing). Two other driving studies reported that the 
drug did not impair manoeuvring ability in healthy volunteers
[61]
 or steering control in young 
insomniacs
[45]
 10-12 hours after a single or multiple doses. Interestingly, temazepam also did 
not affect lateral position, speed deviation or reaction time in a group of elderly volunteers, 
even if they were tested only 5.5 hours after a 2am dose.
[48]
 However one cohort study shows 
that temazepam is associated with increased traffic accident risk during the first four weeks 
of use and to a lesser extent, during an extended period of use.
[28]



































































Loprazolam (6-12 hours): The only study on loprazolam (1mg and 2 mg) shows 
impairment in highway-driving (as measured by SDLP) even 16-17 hours after 2 nightly 
doses in young patients with sleep disturbances.
[5]
 This study also showed strong correlation 
between driving impairment and plasma drug concentration. This long-lasting impairment 
more-closely resembles the pattern observed with long-half-life hypnotics (e.g. flurazepam 
and flunitrazepam) rather than that observed with other intermediate-half-life hypnotics (e.g. 
temazepam). 
Lormetazepam (half-life: 10-12 hours): Effects of lormetazepam on driving was 
tested in 5 experimental studies. Lorazepam 1mg or 2mg administered at night did not have 
significant acute or subchronic effects in the morning on SDLP in patients with insomnia.
[46]
 
Healthy volunteers showed a significant impairment 10 hours after the first two days of 
administration but not 16 hours after the second dose.
[68]
 In driving simulation experiments 
lorazepam 2mg increased tracking errors and reaction time when tested 1-5 hours,
[67]
 but did 




 effects when tested in the morning 
following a nightly dose. 
Short-acting hypnotics which have been tested for the effects on driving include 
triazolam, midazolam, zopiclone, zolpidem, zaleplon and eszopiclone. 
Triazolam (half-life: 2-3 hours):  One driving simulator study showed increased 
tracking errors up to 4.5 hours and delayed brake reaction time up to 1.5 hours after triazolam 
0.25mg,
[69]
 but no significant effects were observed on simulated driving when tested in the 
morning following a 0.25mg or 0.5mg nightly doses.
[59, 77]
 However, given that there is some 
evidence that triazolam may be associated with increased accident risk,
[32]
 it is worth 
investigating drug effects also with on-the-road driving tests. 
Midazolam (half-life: ~ 2 hours):  The only study on midazolam did not show a 





































































Zopiclone (half-life: 5-6 hours): Effects of zopiclone have been tested in 4 
standardised on-the road driving studies and 5 driving simulator experiments. All studies 
used the standard treatment dose of 7.5mg. Despite the short-half life of the drug, there is 
consistent evidence that SDLP increases 5 hours
[81]
 and 10 hours after a bedtime dose in 
healthy young volunteers
[79, 81, 82]
 and 10 hours post-dose in the elderly individuals.
[56]
 One 
driving simulator study also reported increased lateral position deviation 10 hours after 
dosing but not after 12 hours.
[78]
 Other driving simulator studies reported increased collisions 
after 9-11 hours,
[49]
 increased tracking errors after 1.5 hours
[69, 83]
 and delayed brake reaction 
time after 1.5 and 4.5 hours.
[69]
 These findings parallel the markedly high traffic accident risk 
associated with zopiclone in epidemiological studies.
[18, 27]
 This is an unexpected trend given 
the short plasma half-life of zopiclone. 
Zolpidem (half-life: ~ 2 hours): Two actual driving study and 1 simulator study 
examined the effects of zolpidem 10mg around 4-5.5 hours after middle-of the night dosing. 
This dose increased SDLP and SDS in healthy volunteers in both actual driving studies
[79, 84]
 
and increased the variance of lateral position in patients with insomnia in the simulator 
study.
[48]
 Similarly, increased poor lateral position and speed control were reported at 2 
hours, but not 13 hours after a 10mg dose in another driving simulator study.
[85]
 One actual 
driving study  and 2 simulator studies showed that zolpidem 10mg does not impair SDLP in 
young insomniacs,
[47]
 or mean lateral position variance in healthy elderly
[78]
 or young 
insomnia patients,
[49]
 when tested in the following morning (i.e. 9-10 hours post-dose). The 
experimental evidence indicates that a 10mg bedtime dose of zolpidem does not affect the 
basic control processes of driving in the following morning but does impair if taken in the 
middle of the night. The largest cohort study conducted so far reports a two-fold increase in 
traffic accident risk in young zolpidem users during first 4 weeks of use,
[18]
 while another did 
not find a significant increase in the risk.
[28]



































































prescription records, so that neither of the two studies is able to provide information on actual 
time of administration of the hypnotic. There is also a theoretical possibility that even if the 
basic control processes of driving are intact in the morning following a bedtime dose (as has 
been observed in the experimental studies), more complex driving skills required for accident 
avoidance may still be impaired. 
Zaleplon (half-life: 1 hour): Effects of zaleplon had been examined only in 3 on-the-
road driving studies.  They showed that SDLP or SDS in healthy young individuals are not 
affected by 10 or 20 mg dose when tested 10 hours (i.e. morning after a bedtime dose)
[82, 84]
 
or 4-5 hours (i.e. middle of the night dose).
[81, 84]
  
Eszopiclone (half-life: 6 hours): According to the 2 driving experiments conducted so 
far, eszopiclone 3mg did not affect the brake reaction time in either healthy young  or elderly 





Antidepressants have been used in therapeutic doses in almost all studies. Driving 
performance has been tested 1-5 hours after dosing, except in 5 studies
[42, 86-89]
 where drugs 
were given at night and driving was tested on the following morning. 
The effect of antidepressants on automobile driving seems to be mainly determined 
by the sedative effect profile, and probably by the anticholinergic effects of the drugs.  
 
3.2.3.1. Sedating antidepressants 
Amitriptyline: Effects of amitriptyline have been examined in 4 actual driving 





 A comparable driving simulator experiment found increased SDLP 
and headway variability 4 hours after amitriptyline 25mg,
[91]



































































correlation between plasma amitriptyline concentration and SDLP.
[8]
 Only one study tested 
driving on the following morning after nocturnal dose. 
[88]
 The investigators found increased 
SDLP even 13 hours after a 25mg nocturnal dose in patients with neuropathic pain. The other 
4 studies report impaired tracking / steering control
[69, 92, 93]
 and brake reaction time
[69, 94]
 2-5 
hours after a 50mg dose.  
Other tricyclic and related antidepressants: All studies where healthy adult 
volunteers were administered sedative antidepressants in multiple daily doses reported 
increased SDLP. Acute (1-4 hours post-dose) impairment of SDLP has been reported with 
imipramine 50mg b.i.d.,
[95]
 doxepin 25mg t.i.d.,
[5, 96]
 mianserin 10mg t.i.d.
[5, 96, 97]
 Three 
studies on the effects of nocturnal doses showed that SDLP was increased in the following 




 but not after dothiepin 
75mg
[86]
 or mianserin 30mg.
[89]
 The only experimental study on elderly participants show no 
acute effects (2 hours post-dose) of imipramine 50mg on SDLP, although a significant 
increase was observed in their younger counterparts.
[55]
 
Effects of continuing treatment: Post-dose impairment in SDLP remained significant 
even after 1-2 weeks of treatment with mianserin,
[96, 97]









 Only 3 studies examined the subchronic 
effects of sedative antidepressants on driving in patient groups. One study of chronic pain 
patients showed that the impairing effects (as indexed by increased SDLP) of amitriptyline 
disappear after 15 days of continuing treatment.
[53]
 The other two driving simulator studies 
on depressed patients showed improvement of performance after two to four weeks of 
treatment with mirtazepine.
[39, 98]
 The latter study also found that performance did not 







































































In contrast to tricyclic and other sedating antidepressants, newer non-sedating 
antidepressants do not appear to have acute or subacute effects on driving when tested with 
standardised highway driving tests or driving simulation tests. Absence of any significant 
acute or subchronic effects on SDLP or speed variability in healthy volunteers has been 




 and escitalopram (10-
20mg),
[87]
 serotonin-noradrenaline reuptake inhibitor venlafaxine (37.5-75mg b.i.d.)
[97]
 and 
monoamine oxidase inhibitor moclobemide (200mg b.i.d.).
[96]
 The only study on depressed 
patients reports that driving performance (as tested on a simulator) improves after a two-






Only 3 experimental studies examined the effects of opioids on driving 
(Supplementary Table 3). One study on healthy volunteers showed increased collisions in a 
driving simulator task after a single 50mg dose of codeine
[99]
 while the other showed no 
significant acute effects of oxycodone-paracetamol combined  preparation (5mg/325mg and 
10mg/650mg) on SDLP or SDS.
[100]
 However, in the latter study, a dose response 
relationship was observed and subjective reporting indicated that the participants had to 
apply more effort in driving compared to control conditions. The only study on patients with 
chronic pain was a pre-test post-test design where driving performance was tested before and 
2 months after initiation of a transdermal fentanyl treatment.
[41]
 There was no significant 
change in performance as assessed with a driving simulator test. 
 



































































A limited number of experimental studies compared the effects of drugs alone with 
drug-alcohol combinations on driving skills. The addition of alcohol was found to worsen the 










One study reports the interactive effects of diazepam with amitriptyline and with 
mirtazepine. Severity of tracking error was greater with diazepam-antidepressant 





The present paper reviewed the research evidence on the effects of three different 
classes of sedative drugs (benzodiazepines, antidepressants and opioids) on driving 
performance, and their association with traffic accidents, taking into account different drug 
and patient factors that modify these effects in a practical context.  
Our meta-analyses of case-control and cohort studies indicate that benzodiazepines, 
as a group, are associated with 60-80% increase the risk of traffic accidents. Meta-analysis of 
case-control studies on accident culpability shows that drivers responsible for traffic 
accidents are 40% more likely to be positive for benzodiazepines than those who are not 
responsible, suggesting that benzodiazepines actually may play a causative role in traffic 
accidents.  
Deleterious effects of benzodiazepines are potentiated by co-ingestion of other 
sedative substances. The present review shows that presence of alcohol and benzodiazepines 
was associated with 7.7-fold increase in the risk of traffic accident. Evidence from 
experimental studies supports this assertion. Benzodiazepines also interact with sedative 
antidepressants to impair driving skills and increase the risk of accidents. Although drug 



































































drug-alcohol combinations, they do not specify the effects on driving. We believe that drug 
information sheets / warning labels should specify this interactive effect on driving, and 
prescribers should warn patients that the benzodiazepine-alcohol combination may markedly 
increase the risk of accidents even if the blood alcohol levels are below the legal limit 
(generally 0.5-0.8g/dL in most countries).  
Epidemiological studies also suggest that benzodiazepine-associated traffic accident 
risk is less in elderly drivers than in younger adults. Low benzodiazepine-associated accident 
risk in elderly drivers may occur for a variety reasons. Elderly individuals tend to be 
prescribed with lower doses of benzodiazepines compared to their younger counterparts. 
Perhaps elderly drivers on benzodiazepines may appreciate the potential deleterious effects 
of drugs more and resort to safer driving patterns or limit driving while they are on drugs. 
Epidemiological studies however, do not provide information of drug doses or driving 
patterns and thus fail to support or refute any of the above speculations. Only a few driving 
experiments have been carried out in elderly
[54, 56, 57]
 and they do not make a clear distinction 
between drug effects on young and the elderly. Although driving experiments in elderly 
drivers after sedative drugs may have safety and ethical concerns, further research on this 
group is necessary because increased life-expectancy and independence has increased the 
proportion of elderly drivers in the community, and many elderly patients take 
benzodiazepine hypnotics. 
General patterns emerging from epidemiological and experimental studies also 
indicate that anxiolytics, taken in single or multiple doses during daytime tend to impair 
driving somewhat independently of their half-lives. As for hypnotics, the accident risk and 
the possibility of daytime driving impairment tend to be related to their plasma half-lives, but 



































































The results of the experimental studies suggest that diazepam, flurazepam, 
flunitrazepam, nitrazepam and the short-half-life non-benzodiazepine hypnotic zopiclone 
may cause significant driving impairment and the findings of epidemiological studies show 
that  use of these same drugs are associated with a significant increase in traffic accident risk. 
The accident risk remains elevated at least during the first 2-4 weeks after commencement of 
treatment, and nocturnal doses cause impaired driving performance at least up to the 
following afternoon in case of benzodiazepine hypnotics and the following morning in the 
case of zopiclone. Diazepam is the most extensively studied benzodiazepine. Even though 
widely prescribed, there is strong evidence that diazepam worsens driving performance and 
is associated with increased accident risk, at least for the first 3-4 weeks after commencement 
of anxiolytic treatment. Impairing effects of the above sedative drugs raise important, but 
controversial legal implications. The 2-3 fold increase in accident risk associated with these 
long acting benzodiazepines and zopiclone is equivalent to what has been observed with a 
blood alcohol concentration of 0.05-0.08g/dL,
[101, 102]
 which is above legal limits for driving 
in most countries. A series of on-the-road driving studies also illustrate that SDLP observed 
with therapeutic doses of the hypnotics is above these legal limits for alcohol.
[14]
 For 
hypnotic medication, an option for prescribers is to avoid these hypnotics (flurazepam, 
flunitrazepam, nitrazepam and zopiclone) if patients are engaged in driving. Relatively safer 
alternatives would be shorter acting hypnotics such as triazolam, temazepam, zolpidem and 
zaleplon which were not found to cause driving impairment at least in experimental studies 
(although there is evidence that some of the drugs are associated with increased accident 
risk). Still, patients should be cautioned against possible effects on driving and the course of 
hypnotic treatment should be continued only for the minimum required period. We believe in 
the present clinical context, patients with anxiety prescribed diazepam should be strongly 



































































with hypnotics, the research evidence does not readily offer safer alternatives for prescribers: 
all other anxiolytics, with daytime dosing, were found to impair driving, at least in healthy 
volunteers. Large scale epidemiological studies and experimental studies on patient groups 
are imperative to examine the safety of other anxiolytics. 
There is no clear distinction between sedative and non-sedative antidepressants in 
their association with traffic accidents in epidemiological studies, particularly in young 
patients using antidepressants.
[27,28,38]
 Presumably one major source of confounding in patient 
studies is the condition to which the drugs are prescribed (i.e. depression). Antidepressants 
interact differently with depression at different stages of treatment to influence driving 
ability. To begin with, cognitive and psychomotor deficits of depression itself may limit 
driving capacity of an individual. As the antidepressants do not bring therapeutic effects 
immediately after commencement of treatment, patients may show driving impairment 
irrespective of the sedative properties of the antidepressants during the first 1-2 weeks of 
treatment. Patients on sedative antidepressants may be affected more than those on non-
sedating antidepressants during this initial stage due to acute sedative effects of the drugs, as 
has been observed in healthy volunteers in experimental studies. Continuing treatment 
beyond 3-4weeks tends to improve depression and patients tend to become tolerant to 
sedative effects, depression begins to be alleviated and patients may develop tolerance to 
sedative effects of sedating antidepressants. This notion is supported by limited experimental 
evidence which showed that young patient groups treated with sedative or non-sedative 
antidepressants improved their driving skills after a few weeks
[39, 88, 98]
 while untreated 
patients did not.
[98]
  In general epidemiological studies have failed to eliminate residual 
confounding effects of depression, because they have basically compared those who use 
antidepressants (i.e. depressed patients) with those who did not (most likely non-depressed 
individuals).   Case-crossover 
[27]
 and self-controlled case-series 
[28]



































































overcome this methodological constraint by employing with-in subject designs thus 
controlling for depression at least to some extent.  
Limited evidence suggests that TCAs may be associated with an increased traffic 
accident risk in the elderly. Experimental evidence is very scarce on this group and hence it 
is impossible to confirm whether this is due to differential effects of antidepressants, 
depression or a complex interaction between the two. 
Few epidemiological studies conducted so far suggests that opioid users (at least in 
young drivers) may be at a greater risk of traffic accidents in the first few weeks of treatment. 
However, scarce experimental data do not provide conclusive evidence on whether opioids 
impair driving in patients under treatment. Similar to antidepressants, the interactive effect of 
opioids and underlying conditions such as chronic pain on driving performance is also not 
clear. 
  Apart from the biases and limitations of the individual studies, there are certain 
limitations of the present review. We could not include certain epidemiological studies
[22,27,28]
 
in the meta-analyses as they did not contain the necessary information required to calculate 
risk estimates which are compatible with the majority of the studies. However, only the 
magnitudes of the risk estimates of these studies were different from the pooled estimates; 
the direction of association was the same. It has to be also admitted that, even the best efforts 
of combining epidemiological and experimental evidence failed to establish a complete 
causative pathway between psychoactive drugs and traffic accidents. In other words, 
epidemiological studies showed that some these drugs are associated with (but not 
necessarily cause) an increased risk of traffic accidents. Driving performance studies showed 
that those drugs caused an impairment of driving, but this does not necessarily mean that the 
impairment is practically significant enough to increase the risk of accidents. As a 



































































weaving of vehicle as indexed by SDLP) against different levels of exposure to substances 
already known to increase accident risk (e.g. different blood levels of alcohol).
5
 Future 
research can further narrow this gap in the path of causation by correlating the performance 
measures (e.g. SDLP) directly with the risk of accidents of the same subjects (e.g. number of 
traffic accidents the test subjects encounter during a certain fixed time period before and after 
SDLP measurement). In fact, a similar approach had been used recently to validate trail-
making test B performance (which is a neuropsychological measure of visual scanning, 






Although there are inherent limitations in pharmacoepidemiological and experimental 
study designs in detecting the effects of sedative drugs on driving and traffic safety, a clearer 
picture emerges in combining the findings of the two different types of studies. The results 
show that benzodiazepine use is associated with a significant increase in the risk of traffic 
accidents and accident responsibility of drivers. The accident risk is markedly increased by 
co-ingestion of alcohol. Driving impairment was generally related to plasma half-lives of 
hypnotics, but with notable exceptions. Anxiolytics, with daytime dosing, impaired driving 
independent of their half-lives. We believe that these findings will help in formulating more 
specific clinical guidelines and precautions in use of benzodiazepines.  
Limited epidemiological evidence suggests that TCAs may be associated with 
increased accident risk at least in the elderly. Experimental studies also indicate that sedative, 
but not non-sedative antidepressants impair driving performance at the initiation of treatment. 
However, long-term experimental studies with regular follow-up are necessary to elucidate 



































































performance over the course of treatment in depressed patients. Opioid users seem to be at a 
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(0.6 – 2.2) 
Not included in meta-
analysis because of 1) 
questionable accuracy of 
clinical notes in assigning 
at-fault status of drivers. 
2) no adjustment for 
alcohol (more cases 
drinking than controls). 3) 
no direct comparison of 
drivers at fault and not at 
fault.  

























0.8g/l with no 
benzodiazepines 
OR = 0.96 (0.8– 1.2) 
 
OR = 7.2 (3.4 – 15.2) 
 




























matched for age, 
sex, county of 
residence, but 
not met with 























OR = 0.9 (0.4 – 2.0) 
OR = 1.2 (0.5 – 2.7) 
 
 
OR = 2.3 (1.1 – 4.8) 
OR = 0.7 (0.2- 1.9) 
Main benzodiazepine 
triazolam (~50%). 
Exposure status was 
defined in relation to a 
given class of drugs. 
‘Unexposed group’ may 




























































Number of drugs in 
current users 
One type 
>= 2 types 
 
OR = 1.8 (1.0 – 3.4) 
OR = 1.0 (0.5 – 1.8) 
 
 
OR = 1.3 (0.8 – 2.0) 
OR = 2.0 (1.0 – 4.0) 
another class of drug. 
Thus the OR may 
underestimate actual risk. 
Risk of being ‘at-fault’ 
for accidents was also 
higher in those exposed to 
drugs. 
Hemmelgarn 





June 1990 – 
May 1993 






Quebec for at 






(10 per one case) 
who were at risk 
of, but did not 
meet with 
accidents during 
the index date 
Prescription 
records: 
exposed if index 
date included the 
period of 
prescription, not 
exposed if no 
benzodiazepine use 
































OR remains high in 



























and who had 
been registered 




19386 persons  





The day of TA 
Control period: 




Intake of the drug 

































Higher risk with 













benzodiazepines are more 
likely to be responsible 
for TAs. OR for 
benzodiazepines decrease 























culpable for TA 
Detection of drugs 





















Confidence intervals for 
odds ratios are not given. 
These findings are also 
presented in Longo et al., 
2001 with emphasis on 
benzodiazepines. The 































































65y who had a 






TAs from 1 



















At-fault drivers, vs. 
drivers not involved 
in TA 
At-fault vs. not-at- 
fault drivers 
Antidepressants: 
At-fault drivers, vs. 
drivers not involved 
in TA 













OR=1.3 (0.2 -6.7) 
Whether the subjects 
were on medication 
during the time accident 
is not specified. 












admitted due to 
other reasons 
Detection of drugs 
























Detection of drugs 
in blood samples 
Age 
Gender 
No. of vehicles 
in crash 
State 









Only fatal crashes were 
analysed. Small sample 
sizes. 














































OR = 6.1 (2.6–14.1) 
 
OR = 112.2 (14.1-892) 
Controls are a group of 
drivers stopped by police 
at roadside. This may 
have introduced a bias 
towards null if the reason 








1993 - 2006 


























Short-t ½ (<6h): 
midazolam 98% 






OR=1.02 (0.73 – 1.42) 
 
 
OR=1.53 (1.20 – 1.96) 
 
OR=1.44 (1.25 – 1.66) 
Drivers positive for 
alcohol excluded. Age 
stratified results: higher 






















































































































crashes per 1000 
person-years 






for alcohol use 
& driving 
frequency 









BDZ + TCA 
 
RR = 1.5 (1.2– 2.9) 
RR =1.5 (1.1– 2.0), 
risk increases with 
dose. 
RR = 2.2 (1.3 – 3.5), 
risk increases with 
dose. 
RR = 1.1 (0.5 – 2.4) 








1979 - 1986 
323,658 
individuals > 
20y of age 








hypnotic (n=78,070) or 
an anxiolytic 
(n=147,726), but not 
receiving any within 6 
months preceding 
index prescription 
























Within 4 weeks 
Within 2 weeks 
Anxiolytics (oxazepam, 
lorazepam, diazepam): 
Within 4 weeks 
Within 2 weeks 
 
 






OR=3.1 (1.5 – 6.2) 
 
 
OR = 3.9 ( 1.9 – 8.3) 
OR = 6.5 (1.9 – 22.4) 
 
 
OR = 2.5 (1.2 – 5.2) 
OR = 5.6 (1.7 – 18.4) 
Risk reduces with time 
since prescription. 
 
OR = 3.2 (1.4 – 7.3) 
OR = 1.0 (0.3 – 3.7) 
OR = 2.4 (1.0 – 6.3) 
OR = 3.1 (1.4 – 6.5) 
OR = 5.1 (2.3 – 11.6) 
Benzodiazepine 
related odds ratios 
are similar in  
young (<60y) and 
elderly (>60y) 
drivers. However, 
young age group is 
an independent risk 
factor for traffic 
accidents. 
Engeland 















periods: First 7 days / 
14 days after 
dispensing or period 
corresponding to  no. 
of dispensed defined 




for the given 
drug 
TA that resulted 
in a personal 
injury, Incidence 
rate 
Stratified for sex 
and age 
Adjusted for 








Natural opium alkaloids 
 
SIR = 2.9 (2.5 – 3.5) 
 
SIR = 3.3 (2.1 – 4.7) 
 
 




































































periods: First 7 days / 
14 days after 
dispensing or period 
corresponding to  no. 





for the given 
drug 
TA that resulted 











 7 days 
1
st
 14 days 
1
st
 7 days in new users 
 
 
SIR = 2.8 (2.2 – 3.2) 
SIR = 2.5 (2.1 – 3.0) 



















period: number of days 
corresponding to  no. 
of dispensed defined 
daily doses 
Period other 
than the period 
defined as 
exposed period 
TA that resulted 





















SIR = 1.4 (1.2 – 1.6) 




SIR = 1.6 (1.5 – 1.7) 
SIR = 1.6 (1.3 – 1.9) 
 
Gustavsen 















periods: First 7 days / 
14 days after 
dispensing 
Period other 
than the period 
defined as 
exposed time 













 7 days 
1
st




 7 days 
1
st




 7 days 
1
st




 7 days 
1
st
 14 days 
 
SIR = 2.3 (2.0 – 2.8) 
SIR = 2.0 (1.7 – 2.2) 
 
SIR = 2.2 (1.4 – 3.4) 
SIR = 2.1 (1.5 – 2.9) 
 
SIR = 2.7 (1.8 – 3.9) 
SIR = 2.2 (1.6 – 3.0) 
 
SIR = 4.0 (2.4 – 6.4) 
SIR = 3.1 (2.0 – 4.6) 
The degree of the 




Risk is higher in 








1986 - 2004 
 
Individuals 18 
































 Benzodiazepines (all): 
- 1
st
 4 weeks 




            - extended use 
Temazepam - 1st 4 wks 
            - extended use 
Nitrazepam – 1
st
 4 wks 




             - extended use 
Zolpidem – 1
st
 4 wks 




 4 weeks 
- extended use 
IRR (99% CI): 
IRR= 1.94 (1.62–2.32) 
IRR= 2.38 (2.01–2.81) 
IRR= 1.93 (1.54-2.43) 
IRR= 2.77 (2.20-3.48) 
IRR= 1.56 (1.12-2.17)  
IRR= 1.36 (1.02-1.80) 
IRR= 1.66 (0.72-3.86) 
IRR= 1.55 (0.89-2.70) 
IRR= 1.03 (0.68-1.55) 
IRR= 1.40 (1.04-1.87) 
IRR= 1.04 (0.43-2.48) 
IRR= 1.16 (0.60-2.25) 
 
IRR= 1.70 (1.39 -2.08) 






















































 4 weeks 




               - extended use 
Dihydrocodeine 
               –1
st
 4weeks 
              - extended use 
Tramadol – 1
st
 4 weeks 




 4 weeks 




 4 weeks 
- extended use 
IRR= 1.61 (1.11 -2.32) 
IRR= 1.33 (0.88 -2.00) 
IRR= 1.16 (0.39 -3.45) 
IRR= 0.87 (0.43 -1.75) 
 
IRR= 1.60 (1.14-2.25) 
IRR= 1.05 (0.78-1.42) 
IRR = 1.46 (1.02-2.11) 
IRR = 1.34 (1.02-1.76) 
 
IRR= 0.92 (0.75 -1.12) 
IRR= 1.16 (1.06 -1.28) 
 
IRR= 0.92 (0.73 -1.16) 

















period: First 7 days 
after dispensing 
codeine or tramadol 
Unexposed 
period: Period 
not exposed to 
any CNS 
impairing drugs 
TA that resulted 







of other impairing 
drugs excluded) 
Tramadol 
SIR =  1.9 (1.6 – 2.2) 
 
 
SIR = 1.3 (1.0 – 1.6) 





































































Table 3: Experimental study designs (both benzodiazepines and opioids were tested in one study. Some studies administered both actual and 


















Crossover 41 16 1 
Intergroup 4 2 1 
Other 3 2 1 
Study samples 
Healthy volunteers 35 18 2 
Patients 13 3 1 
Driving test 
Simulator 15 6 2 
Actual driving 34 14 1 
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Figure 4
Click here to download high resolution image
Figure 5
Click here to download high resolution image
 
Supplementary table 1: Benzodiazepines and driving performance: experimental studies (All treatments are single oral doses unless specified 
otherwise. 
BAC: blood alcohol concentration. RT: Reaction time. BRT: Brake reaction time. DDD: defined daily dose. SDLP: Standard deviation of lateral 








c) Treatment conditions: 
Drug, dose, duration of 
treatment if >1 dose 
d) Timing of 
test after 
dosing 












In 7 groups (10 
each) 
 
No drug or drink (Zero 
group) 
Placebo drug & drink 
Alcohol 0.5g/kg 
Diazepam 10mg 
Diazepam 10mg + alcohol 
Codeine 30mg 
Codeine 30mg + alcohol  
30 minutes 
40-minute 
drive in a 
driving 
simulator 
Steering wheel reversals, 
number of times brakes  
used, number of times 
clutch used, number of 
times turning signal used, 
Speed, BRT, number of 
neglected instructions, 
number of collisions, 
driving off the road 
Diazepam: More neglected instructions 
and collisions 
Codeine: Less steering wheel reversals 
and more collisions 
Diazepam + alcohol: More steering 
wheel reversals, neglected instructions 
and collisions 
Codeine + alcohol: More collisions 
(All comparisons with the Zero group) 
No comparisons with 
placebo. Any statistical 

















Medazepam 5–30mg /d 
(mean 16.5mg) 
Placebo 
x 3 weeks 
At the end of 3 
weeks. Time 
not specified. 




Driving Simulator: BRT, 
speeding, forgetting 
indications, errors in 
steering and positioning 
Actual driving: major 
(dangerous) or minor 
(technical) driving errors 









10 volunteers (5 
men, 5 women. 
mean age 27y) 
Clobazam 20mg 
Placebo 









No. of errors and time 
taken for gap estimation, 
reverse parking, garage 
parking. 
manoeuvring ability 
Reverse parking delayed with clobazam. 
No other changes. 
Acute effect not 
examined. Negative 
effects on day 7 may be 
due to absence of drug 
















morning for 3 days 





29 variables of driving 
performance: Observer-
rated items and objective 
measurements 
Break reaction time delayed with 
diazepam compared to clobazam. No 
other differences. 
Any statistical 





















t.i.d. x 3 days + 1 dose in 
morning of  4
th
 day 





Reverse parking, three 
point turn, slalom about 
fixed bollards, width 
estimation, BRT 
Poor performance in parking, three-point 
turn, slalom and braking after lorazepam 
compared to clobazam and placebo. 
No difference in any measures between 
clobazam and placebo. 
 
Supplementary tables 1-3





9 patients with 
anxiety (45.6 
±9.6y) and 13 
controls (40.6 
±8.4y) (all men) 
treated by same 
physician  
Diazepam 
5mg – 20mg/d. Duration of 






measured according to a 
checklist by a trained 
observer 




dosing and testing not 
specified. Medical 
conditions of the 




















Poor manoeuvring skills with 
flurazepam. 
More hits on sides in passable gaps after 
both drugs. 
Many drug-unrelated 
factors may have 
increased errors: 
Subjects unfamiliar 
with vehicle, only 2 
minutes of practice. 
Instructions to drive as 












40y) in 3 
groups (8 men 
& 8 women 
each) 
Buspirone 20mg 
Diazepam 15 mg 
Placebo 
daily for 9 days. 
 
Before and 1h 




(~ 30 min) 
Numerous measures: 
Lateral position control 
Speed control 
Headway control 




Day 1, postdose: Worst overall 
performance with diazepam and best 
performance with buspirone. 
Day 8, predose: No significant difference 
among groups. 
Day 8, postdose: Worst performance with 




(0.67xDDD) doses not 
comparable. Analyses 
of extensive number of 
variables, but no 
corrections made for 
multiple comparisons. 
O'Hanlon 





9 healthy male 
driving 













Increased SDLP after 10mg diazepam 
























No impairment with midazolam, alcohol 
















2 nights at 10pm 
10-11h  









Increased SDLP following all active 
treatment conditions, both in the 





























Increased SDLP following all active 
treatment conditions, both in the 
following morning (10-11h) and 
afternoon (16-17h).  
Degree of impairment 

























executions with steering, 
Reaction time 
Flurazepam: less correct tracking 
executions and prolonged reaction time 
compared to placebo 

















Placebo, with out and with 
alcohol 0.6g/kg. 





executions with steering 
Reaction time 
Lormetazepam: impaired correct tracking 
executions and delayed reaction time, 
both with and without alcohol. Drug 
effects potentiated by alcohol 
Diazepam: impaired correct tracking 
executions only at 1h postdose. Delayed 
reaction time throughout. No potentiation 

























test (30 min) 
Driving simulator: BRT 
Actual driving: Number 
of mistakes in an 
avoidance manoeuvre 
No significant differences except delayed 













Placebo 2 days > 
Temazepam 20mg or 
Nitrazepam 10mg x 8 days 
> placebo 3 days 
(dosing at 10pm) 
10h & 16h 
after day 2, 4, 







Temazepam: Minimum or no impairment 
at 10h (morning). No impairment in 
afternoon (16h). 
Nitrazepam: Significant impairment with 























Better performance with temazepam and 
worse performance with flunitrazepam 
on both days. 
 
Brookhuis 










Placebo x 2 nights > 
Lormetazepam 1mg or 
lormetazepam 2mg or 
flurazepam 30mg x 8 nights 
> Placebo x 3 nights 
10h & 16h 
after 2 placebo 
doses 
(baseline), 2, 4 
& 7 active 
drug doses and 









Flurazepam: Significant impairment 
during treatment period. Worse in the 
morning. 
Lormetazepam 1mg or 2mg: No 

















in a driving 
simulator 
Accuracy of different 
responses appropriate for 
each driving scenario 
No significant effect of diazepam 
Simulation closer to 
real-life driving. Wide 
individual variation 
may be due to complex 
tasks and perhaps too 












Flunitrazepam 2 mg 
Flurazepam 30 mg 
Triazolam 0.5 mg Placebo, 
x 4 nights 




dose and then 
10 min after 
alcohol 
Drive 20 km in 
the shortest 




Number of crashes 
Average speed: More impairment with 
flurazepam compared to the other two 
drugs. Additional impairment with 
alcohol. Crashes: Significant drug effect 
and alcohol effect. Multiple comparisons 
not significant. 
Covering a distance in 
shortest possible time, 
which is not a measure 
of safe driving, is a 
demand of the driving 
task. 
Van Laar 








2 groups of 12 
outpatients (6 




Placebo x 7 days > drug 
treatment x 4 weeks > 
placebo x 7 days 
Drug treatment = 
Buspirone 5mg t.i.d. x 1wk 
> 10mg mane, 5mg noon, 
5mg nocte x 3wks; or 
Diazepam 5mg t.i.d. x 4wks 
Evening of 7 
day of each 
treatment 
week, 1.5h 
after last dose 







Standard deviation of 
speed (SDS) 
Buspirone: No impairment in SDLP or 
speed control throughout treatment. 
Diazepam: Marked increase in SDLP 
after 1
st
 week, remain significant up to 
end of 3
rd
 week. Poor speed control after 






































Number of correctly 
executed curve 
navigation manoeuvres 
(TC), reaction time 
Both drugs increased SDLP (oxazepam > 





 doses. No effects in afternoon 
following 2
nd
 dose of either drug. 
Simulated driving: No impairment with 
any of the drugs. No correlation between 
performance & plasma drug 
concentrations. 
Oxazepam given as a 
single dose. Anxiolytic 
treatment is 30-50mg/d 







way crossover  
12 healthy 
volunteers 
Diazepam 15 mg 
Amitriptyline 50mg 
Mirtazepine 15mg 
Diazepam + one other drug 
Placebo 
Before, and 
after 1.5h & 
4.5h 
Driving 
simulator test  
Tracking errors 
RT 
Increased tracking errors and prolonged 
RT at both times with amitriptyline and 
both drug combinations. Tracking error 
severity higher with drug combinations. 
Diazepam prolonged Rt after 1.5h. No 










Zopiclone 7.5 mg 
Triazolam 0.25mg 
Placebo 
Alcohol 0.8 g/kg 
Zopiclone / triazolam + 
alcohol 
Before, and 
after 1,5h & 
4.5h 
Driving 
simulator test  
Tracking errors 
RT 
Drugs alone and in combination with 
alcohol increased RT in both times and 
tracking erros at 1.5h. Triazolam + 
alcohol increased tracking erros at 4.5h. 










men, 6 women. 
19-32y) 
Suriclone 0.4 mg  
Zopiclone 7.5mg 
 Placebo, 
 alone and together  with   
50 mg chlorpromazine 
Before, and  
after 1.5h, 3.5h 
& 6h 
Driving 
simulator test  
Tracking errors 
RT 
Zopiclone increased tracking errors and 
prolonged reaction time after 1.5h. No 
significant effect thereafter. Zopiclone 
chlorpromazine combination prolonged 
RT even at 6h postdose. 
 
O'Hanlon 







men, 8 women, 
25-43y) 
Ondansetron 1mg b.i.d. 
Ondansetron 5mg b.i.d. 




 evening + 7 days 
1h after 
evening dose 







Increased SDLP with diazepam on both 
days but not with ondansetron 
 
O'Hanlon, 












t.i.d. x 9 days starting from 
midnight day 1 
2-3h after 
afternoon dose 








SDLP: increase with both drugs on both 
days. 
Headway maintenance: impairment on 
both days with lorazepam and day 2  but 
not day 9  with suriclone 
 
O'Hanlon, 





24 men and 36 
women with 
anxiety (24-
64y) in 3 
groups 
Lorazepam 2mg (n=18) 
Alpidem 5mg (n=19) 
Placebo (n=19) 
b.i.d. run-in, treatment and 
washout periods, 7, 8 & 6 
days respectively 
Day 1 before 
run-in, Day 8 








Significant increase in SDLP with both 
drugs on both days 8 and 15. Change is 
less with alpidem. 
SDLP of patients were 
similar to those of 
healthy volunteers of 
the previous two studies 
 
Vermeeren 






























Chlorpheniramine 8mg / 
12mg nocte > terfenadine 
60 mg mane 
Flurazepam 30mg night > 
placebo morning 
Placebo mighte & morning 
X 2 cycles 
30min after  
last morning 











RT speed changes of 
leading car  
Flurazepam: Significant increase of 
SDLP and SDS with flurazepam 
compared to other 3 conditions. 
Significant delay in RT compared to 
placebo. 
Chlorpheniramine / terfenadine 
combinations: No significant impairment. 
2 subjects on 
flurazepam were too 
drowsy to complete 













Zaleplon 10/20mg >placebo 
Placebo > zaleplon 10/20mg 
Zopiclone 7.5mg > placebo 
Placebo > zopiclone 7.5mg 
Placebo > placebo  
Bedtime > 5h later 







Zopiclone: Increased after bedtime 
dosing and after middle of the night 
dosing. Worse in latter condition.  
Zaleplon: No significant increase after 
either bedtime or middle of the night 










men, 7 women. 
20-30y) in 2 
groups (9am 
&11am) of 8. 
Zolpidem 10 mg 
Zopiclone 7.5 mg 
Flunitrazepam 1 mg 
placebo 









Mean variance of lateral 
position 
Mean variance of vehicle 
velocity 
Mean variance of lateral position: 
Increased by zopiclone and flunitrazepam 
at 10h but not by zolpidem. No effect by 
any drugs after 12h. 
Mean variance of vehicle velocity: Not 
affected by any of the drugs. 
Demand was ‘to drive 
as quickly as possible’ 
while maintaining 
lateral stability. 
Constant speed was not 
a direct test demand but 













0.5mg morning, 0.5mg 
lunchtime, 1mg bedtime 
Captodiamine 50mg t.i.d. 











Number of errors due to 
clumsiness (slalom task), 
excessive inhibition 
(braking too early, too 
conservative gap 
judging), disinhibition 
(braking too late, forcing 
passage when gap is too 
narrow) 
Lorazepam cause more errors due to 
clumsiness and disinhibition compared to 
captodiamine. No difference in errors due 
to excessive inhibition 
The disinhibitory effect 
of lorazepam is 
noteworthy. 
Vanakoski 




way crossover  
9 young (22-
24y) and 9 old 
(55-77y) 
Young: Diazepam 15mg, 
alcohol 0.8g/kg, placebo 
Old: Diazepam 10mg, 
alcohol 0.7g.kg, placebo 
1.5h before 
and 4h after 
Driving 
simulator test 
BRT, tracking errors 
(simple and complex), 
global driving 
performance 
Impaired reaction time and global driving 
performance in both young and old 
groups after diazepam. Increased simple 
tracking errors in both young and old 
groups in daylight condition. 
 
Van Laar 











b.d. X 7 days 








Significant increase in SDLP with 
lorazepam. No effect on SDS by any of 
the drugs. 
Lack of tolerance to 












Zaleplon 10mg or 20mg 
Zolpidem 10mg or 20mg 
Placebo 








Zolpidem: SDLP and SDS significantly 
increased with both doses. Significant 
dose-response relationship. 
Zaleplon: No significant difference form 
placebo. 
3 subjects on zolpidem 
made excessive erros in 
driving and could not 
complete the test. 
Vermeeren 


















Zopiclone: Significantly increased 
compred to zaleplon and placebo 

























Time length of run,  
number of infractions and 
speed exceedings, time to 
collision 
























6 subjects did not complete driving test 
after alprazolam. Both outcome measures 
significantly impaired after alprazolam 
The SDLP increase 
equivalent to that 
caused by alcohol at a 















Single dose at 2am 
Baseline and 





Lateral position deviation 
Speed deviation 
Reaction time 
Time to collision 
 
Greater lateral position deviation after 
zolpidem but not after temazepam. No 









23 patients (9 
men and 14 
women. 18-
65y) with 
primary   
insomnia 
Zolpidem (10 mg) 
Zopiclone (7.5 mg) 
Lormetazepam (1 mg) 
Placebo 
x 7 nights at 10:30pm 
9-11h (7:30am 
- 9:30am), on 
day 2 & day 8 
Simulated 
driving in light 
traffic  
(~ 60 min) 
Lateral position deviation 
Speed deviation 
Number of collisions 
Zopiclone increased the number of 
collisions. Lormetazepam increased the 











men, 9 women. 
20-45y) 
Alprazolam slow release 
(XR) 1mg 
Alprazolam immediate 









SDLP: Increased with both alprazolam 
preparations. Increase with alprazolam 
IR is twice the increase caused by 
alprazolam XR. 
























No difference in change BRT from 

























No difference in change BRT from 

























Number of collisions, 
standard deviation from 
the speed limit, standard 
deviation of absolute 
speed, standard deviation 
from ideal route 
Number of collisions, standard deviation 
from speed limit and standard deviation 
from ideal route increased with zolpidem 
and zolpidem-melatonin combination at 
2h. No significant difference at 13h. 
 
Leufkens 










Gaboxadol 15mg > placebo 
Zopiclone 7.5mg > placebo 
Placebo > gaboxadol 15mg 
Placebo > zolpidem 10mg 
Placebo > placebo 
11pm > 4am 
9am (10h after 










Both SDLP and SDS increased after 
zopiclone 11pm dose, and zolpidem and 
gaboxadol 4am doses. Only SDS 

























SDLP: Significant increase after 
zopiclone but not temazepam. 
SDS: Significantly higher with zopiclone 
























Number of collisions (of 
5 accident scenarios per 
treatment) 
 
No significant increase with any of the 
drugs. 
Total number of 
collisions among 4 
conditions compared 






Supplementary table 2: Antidepressants and driving performance: experimental studies (All treatments are single oral doses unless specified 
otherwise. 
BAC: blood alcohol concentration. RT: Reaction time. BRT: Brake reaction time. DDD: defined daily dose. SDLP: Standard deviation of lateral 
position. SDS: Standard deviation of speed, b.i.d.: twice a daly, t.i.d.: three times a day) 
 
 
Study a) Design b) Subjects 
c) Treatment conditions: 
Drug, dose, duration if >1 
dose 
d) Timing of 
test after 
dosing 








volunteers in 3 
groups (6 men, 




Amitriptyline 0.8mg /kg 
night &  morning 
Amitriptyline morning only 
Placebo 








(Proportion of steering 
errors to toil correct 
responses) 
Before alcohol: No group differences. 
After alcohol: no change in double 
placebo group, but increased in 
amitriptyline groups. Worst in double 
amitriptyline group. 
Placebo only group did 
not show any 
impairment after 
alcohol despite having a 
BAC of 0.08% which 
can impair driving. 








29y) in 4 
groups (10 
each) 
Imipramine 25mg t.i.d. 
Viloxazine 50mg t.i.d. 
Placebo t.i.d. 





 dose, 7 
doses (day 3), 
21 doses (day 
7) 
Driving test 
with a slalom 
task and a gap 
estimation task 
Number of errors in a 
weaving task 
Gap estimation 
Weaving task: Imipramine increased the 
number of errors, when results collapsed 
across all testing days. No acute effect 
after a single dose. 





















2h postdose: Significant impairment only 
with amitriptyline. 









20 healthy male 
volunteers (22-
32y) 




Placebo t.i.d. x 1day 
1:00h-2:15h 






Increased SDLP following amitriptyline, 
doxepin and mianserin. 1/3 of subjects on 





















in a driving 
simulator 
Mean deviation form 
target 
Increased deviation (poor performance) 








way crossover  
12 healthy 
volunteers 
15 mg of diazepam 
50 mg of amitriptyline 
15 mg of mirtazepine 
Diazepam + one other drug 
Placebo 
Before, and 
after 1.5h & 
4.5h 
Driving 
simulator test  
Tracking errors 
RT 
Increased tracking errors and prolonged 
RT at both times with amitriptyline and 
both drug combinations. Diazepam 











men, 9 women. 
26-54y) 
Moclobemide 200 mg b.i.d. 
Mianserin 10 mg t.i.d. 
Placebo 




daily dose on 







Increased SDLP after mianserin on both 










men, 8 women. 
23-40y) 
Brofaromine 50mg b.i.d. 
Brofaromine 75mg b.i.d. 
Doxepin 25 mg t.i.d. 
Placebo 




daily dose on 







Increased SDLP after doxepin on day 1 











men, 8 women. 
21-45y) 
Dothiepin 75mg night x 
8days + 150mg night x 13 
days 
Fluoxetine 20mg at night x 
22 days 
















No significant effects of either drug on 









16 healthy male 
volunteers (21-
28y) 
Paroxetine 20mg morning 
Paroxetine 40mg morning 
Amitriptyline 50mg & 
25mg morning 
Placebo 
X 8 days 
1.5h & 5h after 
morning dose 







Day 1: Impaired with amitriptyline both 
1.5h & 5h postdose. No impairment with 
paroxetine. 
Day 8: Not impaired by any of the 
treatments. 
 








& 12 elderly 
(60-72y). 6 
men, 6 women 
each. 
Nefazodone 100mg 
Nefazodone 200 mg 
Imipramine 50 mg  
Placebo 
b.i.d. x 7 days 
2.25h after 
morning dose 








Day 1: Imipramine increased SDLP in 
Adult group but not in Elderly group. No 
significant effect after nefazodone. 
Day 7: No significant effect of 
imipramine on SDLP in either group. 
SDS: No significant effect by drugs. 
Effect of TCA 
imipramine is in 











men, 9 women. 
21-35y) 
Mirtazapine 15mg x 7days 
> 30mg x 8days 
Mianserin 30mg x 7days > 
60mg x 8days 











Significant, but minor increase in day 2 
&16 with mirtazapine. 















Venlafaxine 37.5 mg b.i.d. 
x 14 days 
Venlafaxine 37.5 mg b.i.d. 
x 7days > 75 mg b.i.d. x 7 
days 
Mianserin 10 mg t.i.d. x 
7days > 20 mg t.i.d. x 7days 
Placebo t.i.d. x 14 days 
2h postdose on 








SDLP: Increased after mianserin in all 4 
test days. No significant effect with 
venlafaxine. 
SDS: Increased after mianserin 
(compared to placebo) on day 1. No other 
changes. 
7 subjects withdrew due 
to adverse effects of 
venlafaxine or 
mianserin. Results may 











men, 6 women. 
21-44y) 
Tianeptine 12.5 mg 
Tianeptine 37.5 mg, 
Mianserin 30 mg  
Placebo 
1.5h, 3h, 4.5h 
& 6h 
Drive on a 
closed circuit 
at 30 miles/h 
BRT 
Mianserin delayed BRT significantly 
longer than other three conditions. 
Tianeptine 37.5mg causes a marginal 



















Milnacipran 50mg + alcohol 
Placebo 
Placebo + alcohol 









evaluated by instructors  
Impaired with alcohol. Milnacipran has 
no effect compared to placebo and does 
not modify the effect of alcohol. 
 









men, 9 women. 
21-40y) 
Escitalopram 10mg x 7 days 
> 20mg x 8 days 
Mirtazapine 30mg x 7 days 
> 45mg x 8 days 











Mirtazapine: Increased SDLP day 2. No 
effect on day 9 or 16. No effect on SDS. 
Escitalopram: No effect on either SDLP 
or SDS. 
1 subject could not 
complete driving test 
after 30mg single dose 
mirtazapine 
Veldhuijzen 








pain patients (4 




 at night x 15 days 
13h, on day 2 







assessment of driving 
quality. 
Amitriptyline increases SDLP on day 2 
but no significant effect on day 16. No 
difference in subjective assessment of 
driving quality 
SDLP increase by 
amitriptyline after acute 
dosing is similar to that 










men. 25-57y) + 
10 matched 
healthy controls 
Long-term treatment with, 
Reboxetine (for 20 patients) 
Mirtazapine (for 20 
patients) 






Number of collisions 
Before treatment: More collisions in 
patient groups. 
Day 14: Significant decline in collisions 
compared to baseline, with both drugs. 
Number of collisions similar in patients 
and healthy controls in day 14. 
Timing of dosing 

























Variability of headway 
BRT 
1h: No differences between conditions. 
4h: Amitriptyline increased SDLP and 
variability of headway. Paroxetine no 
effect. No differences in BRT. 
Moderate positive 
correlation between 
SDLP and plasma 
amitriptyline 
concentration. 









women, 2 men. 
29-67y), 14 no 
treatment (10 
women, 4 men. 
26-62y) 





2, 9, 16 and 30 
(untreated 
group tested 





Number of crashes, 
deviation of lateral 
position 
Mirtazapine group: Improvement in road 
positioning in day 2, 9, 16, 30 compared 
to baseline. Significant reduction of 
crashes on day 30 compared to baseline. 
Untreated: No improvement of driving 
performance on day 2 or 9. Not tested 
beyond 9 days. 
Significant group difference on day 9. 
Incomplete follow up of 





Supplementary table 3: Opioids and driving performance: experimental studies (All treatments are single oral doses unless specified otherwise. 
SDLP: Standard deviation of lateral position. SDS: Standard deviation of speed) 
 
Study a) Design b) Subjects 
c) Treatment conditions: 
Drug, dose, duration if >1 
dose 
d) Timing of 
test after 
dosing 










In 7 groups   
(10 each) 
 
No drug or drink (Zero 
group) 
Placebo drug & drink 
Alcohol 0.5g/kg 
Diazepam 10mg 
Diazepam 10mg + alcohol 
Codeine 30mg 
Codeine 30mg + alcohol 
30 minutes 
40-minute 
drive in a 
driving 
simulator 
Steering wheel reversals, 
number of times brakes  
used, number of times 
clutch used, number of 
times turning signal used, 
Speed, brake reaction 
times, number of 
neglected instructions, 
number of collisions, 
driving off the road 
Diazepam: More neglected instructions 
and collisions 
Codeine: Less steering wheel reversals 
and more collisions 
Diazepam + alcohol: More steering 
wheel reversals, neglected instructions 
and collisions 
Codeine + alcohol: More collisions 
(All comparisons with the Zero group) 
No comparisons with 
placebo. Any statistical 












23 patients (17 






1month titration period and 
1 month stabilization period  
(median 50micrograms/h) 
period 
Not applicable  
Driving 
simulator task 
Reaction time and errors 
in braking, steering, 
speed and signalling 
No differences in outcome measures 













(SD) age : 24.0 
(1.6)y 












No difference between active drugs and 
placebo conditions in any of the 
measures. Significant dose-response 
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